10x Genomics (NYSE:TXG) CEO Serge Saxonov Sells 10,000 Shares

10x Genomics (NYSE:TXG) CEO Serge Saxonov sold 10,000 shares of 10x Genomics stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $87.58, for a total value of $875,800.00. Following the transaction, the chief executive officer now directly owns 963,181 shares of the company’s stock, valued at $84,355,391.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Serge Saxonov also recently made the following trade(s):

  • On Monday, June 1st, Serge Saxonov sold 10,000 shares of 10x Genomics stock. The stock was sold at an average price of $79.82, for a total value of $798,200.00.
  • On Friday, May 1st, Serge Saxonov sold 10,000 shares of 10x Genomics stock. The stock was sold at an average price of $77.39, for a total value of $773,900.00.

Shares of NYSE:TXG opened at $89.99 on Monday. 10x Genomics has a 52 week low of $45.11 and a 52 week high of $108.36. The business has a fifty day simple moving average of $82.35 and a 200-day simple moving average of $77.55.

10x Genomics (NYSE:TXG) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.22) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.09). The firm had revenue of $71.91 million during the quarter, compared to analyst estimates of $71.67 million. The firm’s revenue for the quarter was up 34.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.25) earnings per share.

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. raised their price target on 10x Genomics from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Citigroup raised their price target on 10x Genomics from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Cowen raised their price target on 10x Genomics from $68.00 to $85.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 12th. Finally, Zacks Investment Research downgraded 10x Genomics from a “buy” rating to a “hold” rating in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $84.00.

A number of institutional investors have recently modified their holdings of the stock. Citigroup Inc. acquired a new position in shares of 10x Genomics during the fourth quarter worth about $38,000. Baillie Gifford & Co. acquired a new position in shares of 10x Genomics during the first quarter worth about $99,000. Russell Investments Group Ltd. acquired a new position in shares of 10x Genomics during the first quarter worth about $119,000. Rockefeller Capital Management L.P. acquired a new position in shares of 10x Genomics during the first quarter worth about $138,000. Finally, Bank of America Corp DE lifted its stake in shares of 10x Genomics by 2,716.0% during the fourth quarter. Bank of America Corp DE now owns 2,112 shares of the company’s stock worth $161,000 after purchasing an additional 2,037 shares in the last quarter.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems. It offers chromium instruments, enzymes, reagents, microfluidic chips, and other consumable products, as well as software for analyzing biological systems.

Featured Article: What is a Buy-Side Analyst?

Insider Buying and Selling by Quarter for 10x Genomics (NYSE:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.